INTRODUCTION
Galactorrhea may be associated with various medical conditions or can be caused by several pharmacological agents, a mechanism which needs to be differentiated from other neuroendocrinological disorders 1 . There are a significant number of studies reporting that all selective serotonin reuptake inhibitors (SSRI) are associated with galactorrhea and/or prolactin abnormalities (hyperprolactinaemia), but the number of reported cases is limited [2] [3] [4] [5] [6] 8, 9 . Endocrine side effects of fluoxetine are uncommon and galactorrhea is rarely mentioned 10 . A detailed search of medical literature in English and Turkish revealed just eight cases of fluoxetine-induced galactorrhea 4, 7, 9, 10, 11 . We present a case, which developed galactorrhea following treatment with fluoxetine.
CASE
A 35-year old woman with major depressive disorder, according to the DSM-IV was started on treatment of fluoxetine 20 mg/day. After 3 weeks of treatment, her complaints started to decline. During her subsequent follow-up, she showed significant improvement with minimal side effects. By the 9 th month of treatment with fluoxetine 20 mg, she reported milk discharge from both nipples. Upon physical examination, bilateral breast secretion was expressed without any tenderness. After consulting a gynecologist, hormonal testing in addition to routine systemic evaluation was ordered. There were no abnormalities in the results of laboratory tests such as TSH, fT3, fT4, FSH or LH. Serum prolactin level was within the normal range (8 ng/mL) and B-HCG was
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Bulletin of Clinical Psychopharmacology 2014;24(3):265-7 n e g a t i v e. C r a n i a l M R I a l s o s h ow e d n o pathological lesions in the hypothalamic/ pituitary area. Because of the temporal relationship between the drug administration and onset of galactorrhea and due to the lack of any other underlying medical condition, we stopped fluoxetine treatment. Ten days after drug cessation, the galactorrhea disappeared. T h e p a t i e n t r e f u s e d t o u s e a n y o t h e r antidepressants, so we decided to provide supportive psychotherapy and follow-up; however, after a few months her depressive symptoms relapsed. She decided to try fluoxetine again because she had a history of prior positive response. We started 20 mg/day of fluoxetine after obtaining informed consent concerning the possibility of galactorrhea. Three months later, she reported galactorrhea a g a i n . A l l t h e m e d i c a l a n d l a b o r a t o r y examinations, which were repeated, revealed no underlying pathology. Serum prolactin level was again within the normal range (8.3 ng/mL). Therefore, fluoxetine was stopped for the second time followed by the resolution of galactorrhea on the fifth day. An objective causality assessment using Naranjo Adverse D r u g P r o b a b i l i t y S c a l e s u g g e s t e d t h a t fluoxetine was the definite cause of the galactorrhea (score was 10 out of 13) 12 . After a two-week wash-out period without any antidepressant, a small dose of sertraline was administered and increased slowly. She is now on sertraline 100 mg/day treatment with no r e e m e r g e n c e o f g a l a c t o r r h e a o r hyperprolactinaemia for almost a year.
DISCUSSION
Although the occurrence of galactorrhea induced with fluoxetine use is very rare, several cases have been reported in the literature 4,7,9-11 . To our knowledge, this is the third reported case with normoprolactinemic galactorrhea secondary to fluoxetine treatment as shown in the table (Table  1 ). In our case, there was a relatively later onset galactorrhea in both trials with fluoxetine (9 months and 3 months respectively). This case is also important in the context of practical implications. Although all of the SSRIs share the same mechanism of actions, therapeutic and side effect profiles, each patient reacts differently to a particular SSRI. No two SSRIs have identical secondary pharmacological characteristics 10 . Although there are several case reports about the endocrinological side effects of sertraline such as galactorrhea 2, 5, 8 , we observed no significant adverse effects in our case during a one-year follow-up. With the exception of fluoxetine, all SSRIs commonly cause hyperprolactinaemia through presynaptic mechanisms indirectly via 5-hydroxytryptamine-mediated inhibition of tuberoinfundibular dopaminergic neurons 10 . Hypothetically serotonin regulates prolactin release either by increasing the oxytocin level via direct stimulation of vasoactive intestinal protein or indirectly through stimulation of GABAergic neurons 10, 13 . However, according to some researchers approximately 30% of the patients presenting with galactorrhea may have normal serum prolactin levels 14 . There are some other cases reporting normoprolactinemic galactorrhea associated with SSRI use, and only one case with late onset associated with venlafaxine 15 ; however, t h e e x a c t m e c h a n i s m s t i l l r e m a i n s u n k n o w n 5 , 9 , 1 1 , 1 6 , 1 7 . N o r m o p r o l a c t i n e m i c galactorrhea may be related to an effect on thyroid releasing hormone (TRH). TRH sensitivity may be another factor that plays a role in the emergence of galactorrhea 18 . Alternatively, euprolactinemic galactorrhea is hypothesized to be caused by indirect inhibition of tuberoinfundibular dopaminergic neurons 19 . It is also possible that the prolactin levels of our patient, although in the reference range, were higher than this patient's normal and thus capable of producing pathology. In fact, in most of the reported cases with hyperprolactinaemia secondary to SSRIs, prolactin levels were just slightly above the upper limit 7, 17 . The increasing number of case reports on SSRIrelated neuroendocrine side effects might be signifying a possible endocrine-disrupting effect of SSRIs. Trenque, using data from the spontaneous-reporting French Pharmacovigilance Data in his study, reported that treatment with serotonin reuptake inhibitors (SRIs) was a s s o c i a t e d w i t h a n i n c r e a s e d r i s k o f hyperprolactinaemia. He also suggests that the risk of hyperprolactinaemia should be mentioned in the labeling of SRI compounds 20 . Therefore, larger studies about the effect of SSRIs on the hypothalamic-pituitary axis are needed in order to draw attention to the need of well-designed studies about endocrine side effects of SRIs.
